Surveillance of antibiotic resistance

Current Opinion in Infectious Diseases

Volumn 12, Issue 4, 1999, Pages 321-326

  Verhoef, Jan ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; BETA LACTAMASE; CEFTRIAXONE; CHLORAMPHENICOL; ERYTHROMYCIN; FOOD ADDITIVE; GENTAMICIN; GLYCOPEPTIDE; GROWTH PROMOTOR; KANAMYCIN; MACROLIDE; METICILLIN; PENICILLIN G; PSEUDOMONIC ACID; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TEICOPLANIN; TETRACYCLINE; TOBRAMYCIN; VANCOMYCIN;

ACINETOBACTER; AGED; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL GENETICS; BACTERIAL INFECTION; CASE REPORT; COMMUNITY; DISEASE CARRIER; DISEASE CONTROL; ENTEROBACTERIACEAE; ENTEROCOCCUS; GRAM NEGATIVE INFECTION; HOSPITAL INFECTION; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; KLEBSIELLA; KLEBSIELLA PNEUMONIAE; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; PUBLIC HEALTH; RECURRENT DISEASE; STAPHYLOCOCCUS EPIDERMIDIS; STAPHYLOCOCCUS INFECTION; STREPTOCOCCUS GROUP A; STREPTOCOCCUS INFECTION;

EID: 0032825954     PISSN: 09517375     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001432-199908000-00002     Document Type: Article

References (50)

1. McGowan JE Jr, Metchock BG. Penicillin-resistant pneumococci - an emerging threat to successful therapy. J Hosp Infect 1995; 30 (Suppl.):472-482.
2. Neu HC. The crisis in antibiotic resistance. Science 1992; 257:1064-1073.
3. Rubinstein E, Rubinovitch B. Treatment of severe infections caused by penicillin-resistant pneumococci. Role of third generation cephalosporins. Infection 1994; 22 (Suppl. 3):S161-166.
4. Voss A, Milatovic D, Wallrauch-Schwarz C, Rosdahl VT, Braveny I. Methicillin-resistant Staphylococcus aureus in Europe. Eur J Clin Microbiol Infect Dis 1994; 13:50-55.
5. Schmitz FJ, Fluit AC, Gondolf M, Beyrau R, Lindenlauf E, Verhoef J, et al. The prevalence of aminoglycoside resistance and corresponding resistance genes in clinical isolates of staphylococci from 19 European hospitals. J Antimicrob Chemother 1999; 253-259. This article describes the spread of resistance genes and the linking of various resistance genes. Interesting!
6. Wright CL, Byrne ME, Firth N, Skurray RA. A retrospective molecular analysis of gentamicin resistance in Staphylococcus aureus strains from UK hospitals. J Med Microbiol 1988; 47:173-178.
7. Gillespie MT, Lyon BR, Messerotti U, Skurray RA. Chromosome- and plasmid-mediated gentamicin resistance in Staphylococcus aureus encoded by Tn4001. J Med Microbiol 1987; 24:139-144.
8. Aubry-Damon H, Legrand P, Brun-Buisson C, Astier A, Soussy C-J, Leclerq R. Reemergence of gentamicin-susceptible strains of methicillin-resistant Staphylococcus aureus: roles of an Infection Control Program and changes in aminoglycoside use. Clin Infect Dis 1997; 25:647-653.
9. Hiramatsu K, Aritaka N, Hanaki H, Kawasaki S, Hosoda Y, Hori S, et al. Dissemination in Japanese hospitals of strains of Staphylococcus aureus heterogeneously resistant to vancomycin. Lancet 1997; 350:1670-1673.
10. Centers for Disease Control. Staphylococcus aureus with reduced susceptibility to vancomycin - United States. MMWR 1997; 46:765-766.
11. Felmingham D, Brown DF, Soussy CJ. European Glycopeptide Susceptibility Survey of Gram-positive bacteria for 1995. European Glycopeptide Resistance Survey Study Group. Diagn Microbiol Infect Dis 1998; 31:563-571.
12. Sieradzki K, Roberts RB, Haber SW, Tomasz A. The development of vancomycin resistance in a patient with methicillin-resistant Staphylococcus aureus infection. N Engl J Med 1999; 340:517-523. Interesting and informative!
13. Moreira B, Boule-Vavra S, Boudewijn L, Dejonge M, Daum RS. Increased production of penicillin-binding protein 2, increased detection of other penicillin-binding proteins, and decreased coagulase activity associated with glycopeptide resistance in Staphylococcus aureus. Antimicrob Agents Chemother 1997; 41:1788-1793.
14. Sieradzki K, Tomasz A. Inhibition of cell wall turnover and autolysis by vancomycin in a highly vancomycin-resistant mutant of Staphylococcus aureus. J Bacteriol 1997; 179:2557-2566.
15. Waldvogel FA. New resistance in Staphylococcus aureus [Editorial]. N Engl J Med 1999; 340:556-557. An instructive and thoughtfully written editorial.
16. Johnson AP. Intermediate vancomycin resistance in Staphylococcus aureus: a major threat or a minor inconvenience? [Editorial]. J Antimicrob Chemother 1998; 42:289-291. See comments in Ref. [15**].
17. Woodford N, Johnson AP, Morrison D, Speller DCE. Current perspectives on glycopeptide resistance. Clin Microbiol Rev 1995; 8:585-615.
18. Brunet F, Vedel G, Dreyfus F, Vaxelaire JF, Giraud T, Schremmer B, Monsallier JF. Failure of teicoplanin therapy in two neutropenic patients with staphylococcal septicemia who recovered after administration of vancomycin. Eur J Clin Microbiol Infect Dis 1990; 9:145-147.
19. Kaatz GW, Seo SM, Dorman NJ, Lerner AL. Emergence of teicoplanin resistance during therapy of Staphylococcus aureus endocarditis. J Infect Dis 1990; 162:103-108.
20. Fitch L, Johnson AP. Reduced susceptibility to teicoplanin in a methicillin-resistant strain of Staphylococcus aureus. J Antimicrob Chemother 1998; 41:578.
21. Tenover FC, Lancaster MV, Hill BC, Steward CD, Stocker SA, Hancock GA, et al. Characterization of staphylococci with reduced susceptibilities to vancomycin and other glycopeptides. J Clin Microbiol 1998; 38:1020-1027.
22. Mulder JG, Kosterink JGW, Degener JE. The relationship between the use of flucloxacillin, vancomycin, aminoglycosides and ciprofloxacin and the susceptibility patterns of coagulase-negative staphylococci recovered from blood cultures. J Antimicrob Chemother 1997; 40:701-706.
23. Pagano L, Tacconelli E, Tumbarello M, Laurenti L, Mele L, Spanu T, et al. Teicoplanin-resistant coagulase-negative staphylococcal bacteraemia in patients with haematological malignancies: a problem of increasing importance. J Antimicrob Chemother 1997; 40:738-740.
24. Weinstein JW, Roe M, Towns M, Sanders L, Thorpe JJ, Corey GR, Sexton DJ. Resistant enterococci; a prospective study of prevalence, incidence and factors associated with colonization in a university hospital. Infect Control Hosp Epidemiol 1996; 17:36-41.
25. Murray B. Vancomycin-resistant enterococci. Am J Med 1997; 101:284-293.
26. Perichon B, Reynolds P, Courvalin P. VanD-type glycopeptide-resistant Enterococcus faecium BM4339. Antimicrob Agents Chemother 1997; 41:2016-2018.
27. Morris JG, Shay DK, Hebden N. Enterococci resistant to multiple antimicrobial agents including vancomycin. Ann Intern Med 1995; 123:250-259.
28. Fridkin SK, Yokoe DS, Whitney CG, Onderdonk A, Hooper DC. Epidemiology of a dominant clonal strain of vancomycin-resistant Enterococcus faecium at separate hospitals in Boston, Massachusetts. J Clin Microbiol 1998; 36:965-970.
29. Van den Braak N, Belkum A, Van Keulen M, Vliegenthart J, Verbrugh HA, Endtz HP. Molecular characterization of vancomycin-resistant enterococci from hospitalized patients and poultry products in the Netherlands. J Clin Microbiol 1998; 36:1927-1932. See [28**]. This and [29**] are important papers on the difficulties encountered in VRE epidemiology.
30. Schmitz F-J, Hertel B, Hofmann B, Scheuring S, Verhoef J, Fluit AC, et al. Relationship between mutations in the coding and promotor regions of norA genes in 42 unrelated clinical isolates of Staphylococcus aureus and the MICS for these strains [Letter]. J Antimicrob Chemother 1998; 42:561-563.
31. Kaatz GW, Seo SM, Ruble CA. Efflux-mediated fluoroquinolone resistance in Staphylococcus aureus. Antimicrob Agents Chemother 1993; 37:1086-1094.
32. Yoshida H, Bogaki M, Nakamura S, Ubukata K, Konno M. Nucleotide sequence and characterization of the Staphylococcus aureus norA gene, which confers resistance to quinolones. J Bacteriol 1990; 172:6942-6949.
33. Schmitz F-J, Lindenlauf E, Hofmann B, Fluit AC, Verhoef J, Heinz H-P, Jones ME. The prevalence of low- and high-level mupirocin resistance in staphylococci from 19 European hospitals. J Antimicrob Chemother 1998; 42:489-495.
34. Medeiros AA. Evolution and dissemination of β-lactamases accelerated by generations of β-lactam antibiotics. Clin Infect Dis 1997; 24 (Suppl. 1):S19-S45.
35. Livermore DM, Yuan M. Antibiotic resistance and production of extended-spectrum β-lactamases amongst Klebsiella spp. from intensive care units in Europe. J Antimicrob Chemother 1996; 39:409-424.
36. Shannon K, Stapleton P, Xiang X, Johnson A, Beattie H, ElBakri F, et al. Extended spectrum β-lactamase-producing Klebsiella pneumoniae strains causing nosocomial outbreaks of infection in the United Kingdom. J Clin Microbiol 1998; 36:3105-3110.
37. Yuk-Fong Liu P, Tung J-C, Ke S-C, Chen SL. Molecular epidemiology of extended-spectrum β-lactamase-producing Klebsiella pneumoniae isolates in a district hospital in Taiwan. J Clin Microbiol 1998: 2759-2762. See [36z.ast;] This and [37z.ast;] are nice pieces of work on epidemiology!
38. Peña C, Pujol M, Ardanuy C, Ricart A, Pallares R, Linares J, et al. Epidemiology and successful control of a large outbreak due to Klebsiella pneumoniae producing extended-spectrum β-lactamases. Antimicrob Agents Chemother 1998; 53-58.
39. Shannon K, Fung K, Stapleton P, Anthony R, Power E, French G. A hospital outbreak of extended-spectrum β-lactamase-producing Klebsiella pneumoniae investigated by RAPD typing and analysis of the genetics and mechanisms of resistance. J Hosp Infect 1998; 39:291-300.
40. M'Zali FH, Heritage J, Gascoyne-Binzi DM, Denton M, Todd NJ, Hawkey PM. Transcontinental importation into the UK of Escherichia coli expressing a plasmid-mediated AmpC-type beta-lactamase exposed during an outbreak of SHV-5 extended spectrum beta-lactamase in a Leeds Hospital. J Antimicrob Chemother 1997; 40:823-831.
41. Branger C, Lesimple AL, Bruneau B, Berry P, Lambertzechovsky N. Long-term investigation of the clonal dissemination of Klebsiella pneumoniae isolates producing extended-spectrum beta-lactamases in a university hospital. J Med Microbiol 1998; 47:201-209.
42. Muder RR, Brenne C, Drenning SD, Stout JE, Wagener MM. Multiple antibiotic-resistant Gram-negative bacilli in a long-term-care facility: a case-control study of patient risk factors and prior antibiotic use. Infect Control Hosp Epidemiol 1997; 18:809-813.
43. Afzal-Shah M, Livermore DM. Worldwide emergence of carbapenem-resistant Acinetobacter spp. [Letter]. J Antimicrob Chemother 1998; 41:576-577.
44. Seppälä H, Klaukka T, Vuopio-Varkila J, Muotiala A, Helenius H, Lager K, Huovinen P. The effect of changes in the consumption of macrolide antibiotics on erythromycin resistance in group A streptococci in Finland. N Engl J Med 1997; 337:441-446.
45. Fluit AC, Schmitz FJ, Jones ME, Acar J, Gupta R, Verhoef J for the SENTRY Participants Group, 1998. Antimicrobial resistance among community-acquired pneumonia isolates in Europe: first results from the SENTRY antimicrobial Surveillance program 1997. J Infect Dis 1999.
46. Resisting resistance. The Economist, 31 May 1997; pp 87-88.
47. WHO Regional Publications. Guidelines for Antimicrobial Resistance Surveillance. Eastern Mediterranean Series 15; 1997.
48. Levy SB. The challenge of antibiotic resistance. Scientific American 1998; 278:32-39.
49. Report of the ASM task force on antibiotic resistance. American Society for Microbiology; 1995.
50. Verhoef J, Gupta R. Surveillance of resistance against antimicrobial agents - a European perspective. J Hosp Infect 1999.